ARRY-543: Phase Ib/II start

Next year, ARRY will begin a Phase Ib/II trial of ARRY-543 in combination with Erbitux cetuximab. ImClone Systems Inc. (IMCL, New York, N.Y.) and Bristol-Myers Squibb Co. (BMY, New York, N.Y.) mark...